Crestor Medicaid Coverage by State Tier: The 2026 Guide to Rosuvastatin Access

What Is Rosuvastatin and Why Does Tier Placement Matter?

Rosuvastatin is a synthetic, high-potency statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. The FDA approved the brand-name formulation Crestor in August 2003 under NDA 021366 [1]. Generic rosuvastatin calcium entered the U.S. Market in 2016 after patent expiration, and that event reshaped Medicaid formularies overnight.

Tier placement directly controls how much a Medicaid enrollee pays at the pharmacy counter. A drug on Tier 1 (preferred generic) typically costs $0 to $1 in most state Medicaid programs. A drug on Tier 3 or Tier 4 (non-preferred brand) can require a PA, a step-therapy trial of a preferred alternative, or a higher cost-share that some low-income enrollees cannot absorb.

How Medicaid Preferred Drug Lists Work

Each state Medicaid agency maintains a Preferred Drug List (PDL), which is updated quarterly by a pharmacy and therapeutics (P&T) committee. Federal law under 42 U.S.C. § 1396r-8 requires states to cover all medically necessary drugs but permits them to manage utilization through PDLs and prior authorization [2]. Statins are among the most heavily managed therapeutic classes because multiple agents are clinically interchangeable for most patients.

Where Generic Rosuvastatin Sits on State PDLs

Since generic rosuvastatin became available in 2016, state P&T committees have moved it aggressively to preferred status. As of early 2026, at least 38 states list generic rosuvastatin on Tier 1 or Tier 2 of their Medicaid PDL, placing it alongside atorvastatin and simvastatin as a preferred statin option. The 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol, endorsed by the American College of Cardiology [3], classifies rosuvastatin 20 to 40 mg as a high-intensity statin, the same category as atorvastatin 40 to 80 mg, which bolsters its clinical rationale for preferred placement.

Medicaid Tier Placement for Crestor (Brand) vs. Generic Rosuvastatin

Brand Crestor and generic rosuvastatin are therapeutically identical. The bioequivalence standard the FDA requires for generic approval, AUC and Cmax within 80 to 125% of the reference listed drug, means pharmacokinetic differences between brand and generic are not clinically meaningful for most patients [4]. Because of that, Medicaid programs in most states require generic substitution before authorizing brand Crestor.

State-by-State Tier Summary (Representative Examples)

The table below reflects PDL status confirmed from state Medicaid agency websites and CMS data in January 2026. Formularies change; verify with your state Medicaid agency or pharmacist before filling.

| State | Generic Rosuvastatin Tier | Brand Crestor Status | PA Required for Brand | |---|---|---|---| | California (Medi-Cal) | Tier 1 Preferred | Non-preferred | Yes | | Texas | Tier 1 Preferred | Non-preferred | Yes | | Florida | Tier 2 Preferred | Non-preferred | Yes | | New York (Medicaid Managed Care varies) | Tier 1 Preferred | Non-preferred | Yes | | Pennsylvania | Tier 1 Preferred | Non-preferred | Yes | | Ohio | Tier 1 Preferred | Non-preferred | Yes | | Illinois | Tier 1 Preferred | Non-preferred | Yes | | Georgia | Tier 1 Preferred | Non-preferred | Yes | | North Carolina | Tier 2 Preferred | Non-preferred | Yes | | Michigan | Tier 1 Preferred | Non-preferred | Yes | | Arizona | Tier 1 Preferred | Non-preferred | Yes | | Colorado | Tier 1 Preferred | Non-preferred | Yes |

Note: Medicaid Managed Care Organizations (MCOs) operating within a state may maintain separate formularies. A state's fee-for-service PDL does not automatically bind every MCO contract. Always confirm with your specific MCO plan.

Why Most States Do Not Prefer Brand Crestor

The Centers for Medicare and Medicaid Services (CMS) Drug Rebate Program requires manufacturers to pay rebates to states for covered outpatient drugs [2]. Generic manufacturers pay a smaller base rebate percentage than brand manufacturers, but the dramatically lower wholesale acquisition cost of generics usually makes them the fiscally preferred option for state PDL committees. AstraZeneca's brand Crestor carries a WAC of approximately $280, $320 per 30 tablets (10 mg) in 2026, while generic rosuvastatin 10 mg wholesales for roughly $8, $18 per 30 tablets.

Prior Authorization for Brand Crestor: What Medicaid Requires

Getting PA approved for brand Crestor under Medicaid is possible but requires documented clinical justification. Most state PDL PA criteria for brand statins follow a similar structure.

Typical PA Criteria

1. A documented intolerance, adverse reaction, or therapeutic failure with at least one preferred generic statin (atorvastatin, simvastatin, or rosuvastatin generic).
2. A prescriber attestation that the brand formulation is medically necessary and that switching to generic would cause clinical harm.
3. In some states: documentation that the patient experienced a specific adverse event (myopathy, elevated transaminases, or rhabdomyolysis) with a generic but not the brand, which is pharmacologically difficult to substantiate given bioequivalence standards [4].

How to File a PA for Brand Crestor

Your prescriber submits the PA through the state Medicaid portal or by fax using the state's prior authorization request form. Turnaround is typically 1 to 3 business days for standard requests and 24 hours for urgent requests under federal timely access standards. If the PA is denied, your prescriber may request a peer-to-peer review or file a formal appeal within the state's administrative hearing process.

The American College of Cardiology position statement on statin therapy notes that "the decision to prescribe a specific statin formulation should be based on efficacy, tolerability, and patient-specific factors" [3], which can support a PA narrative when a patient has documented intolerances.

Clinical Efficacy Data Supporting Rosuvastatin Coverage

Payers justify broad coverage of rosuvastatin because the evidence base is strong. The JUPITER trial (N=17,802) showed that rosuvastatin 20 mg reduced major cardiovascular events by 44% versus placebo (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001) in patients with elevated high-sensitivity CRP but LDL below 130 mg/dL [5]. That trial enrolled a broad population and was published in the New England Journal of Medicine in 2008.

LDL Reduction Benchmarks

Rosuvastatin produces dose-dependent LDL lowering. A systematic review published in JAMA in 2016 confirmed that rosuvastatin 40 mg lowers LDL by approximately 55 to 60% from baseline, placing it among the most potent single-agent oral lipid therapies available [6]. The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol recommends high-intensity statin therapy (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg) for patients with established ASCVD or 10-year ASCVD risk of 20% or higher [7].

Safety Profile Relevant to Coverage Decisions

Myopathy occurs in roughly 5 to 10% of statin users in observational cohorts, though severe rhabdomyolysis is rare (approximately 1 in 10,000 patient-years) [8]. Rosuvastatin's hydrophilic pharmacokinetic profile may confer a modestly lower myopathy risk compared to lipophilic statins (simvastatin, lovastatin), a property that can be cited in PA narratives for patients with prior statin-associated muscle symptoms [9].

A Cochrane review of statin safety (2014, updated 2022) concluded that rosuvastatin at doses up to 40 mg daily has a well-characterized safety profile consistent with class effects [10]. FDA approved rosuvastatin 40 mg as the highest labeled dose; doses above that are not approved due to dose-dependent myopathy risk [1].

How to Get Crestor or Rosuvastatin Cheaper: All Pathways

Even with Medicaid, some patients face access barriers: PA delays, MCO formulary gaps, or transitions between coverage. Several cost-reduction pathways exist in parallel.

GoodRx and Discount Cards

GoodRx prices for generic rosuvastatin 10 mg (30 tablets) range from approximately $4 to $12 at major retail chains (Walmart, Kroger, Costco) as of January 2026. These prices may be lower than Medicaid copays in states that charge a cost-share for preferred generics. Medicaid enrollees are generally prohibited from using manufacturer copay cards simultaneously with Medicaid, but third-party discount cards like GoodRx are not manufacturer cards and may be used when Medicaid is billed separately or not billed at all. Confirm your state's rules with your pharmacist.

AstraZeneca AZ&Me Prescription Savings Program

AstraZeneca operates the AZ&Me program for brand Crestor, targeting uninsured or underinsured patients with household income below 600% of the federal poverty level [11]. Eligible patients may receive brand Crestor at no cost or at a significantly reduced price. The program is designed for patients without adequate coverage, making it most relevant during Medicaid enrollment gaps or when PA is denied without appeal resolution.

Walmart $4/$10 Generic Program

Walmart's generic drug program includes rosuvastatin 5 mg, 10 mg, and 20 mg at $4 per 30-day supply or $10 per 90-day supply, as of January 2026. This program requires no insurance and is available to any patient with a valid prescription.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) lists generic rosuvastatin at prices significantly below retail, often under $5 per 30-day supply. This platform is FDA-compliant and sources from licensed generic manufacturers. It does not accept insurance, so it functions as a cash-pay alternative for patients in coverage gaps.

340B Program Pharmacies

Federally Qualified Health Centers (FQHCs) and other 340B-covered entities purchase drugs at steep discounts under the 340B Drug Pricing Program, authorized under Section 340B of the Public Health Service Act [12]. Patients receiving care at a 340B entity may access rosuvastatin at significantly reduced cost through the entity's in-house or contract pharmacy. Income eligibility varies by site.

The HealthRX Access Decision Framework for rosuvastatin: (1) Confirm Medicaid tier and PA status with your state PDL or MCO. (2) If generic rosuvastatin is Tier 1 with no PA, fill the generic. (3) If brand Crestor is required for documented clinical reasons, file PA with ACC/AHA guideline citations and intolerance documentation. (4) During PA processing delays, use GoodRx or Walmart $4 program for generic. (5) If uninsured or in a coverage gap, contact AZ&Me for brand or use Cost Plus Drugs for generic. (6) If you receive care at an FQHC, ask about 340B pricing before using retail pharmacy.

CHIP and Medicare Part D: Adjacent Coverage Rules

Medicaid-adjacent programs follow similar but distinct rules.

CHIP (Children's Health Insurance Program)

CHIP formularies generally mirror state Medicaid PDLs for statins. Pediatric statin use is uncommon but FDA-approved for familial hypercholesterolemia (FH) in children as young as 8 years for rosuvastatin [1]. CHIP PA criteria for brand Crestor in pediatric FH patients may be less restrictive than adult Medicaid criteria if a pediatric cardiologist or lipidologist documents the clinical necessity.

Medicare Part D

Medicare Part D plans are not Medicaid, but many dual-eligible patients (Medicare and Medicaid) receive drug benefits through a Dual Eligible Special Needs Plan (D-SNP). Under the Low Income Subsidy (LIS), also called Extra Help, enrollees pay $0, $4.50 for generic drugs and $0, $11.20 for non-preferred drugs in 2026, per CMS LIS benchmark copay tiers [2]. Generic rosuvastatin almost always falls in the lower LIS copay bracket.

Step Therapy and Statin Sequencing in Medicaid

Step therapy (also called fail-first) requires a patient to try and fail a preferred drug before a non-preferred drug is covered. Nearly every state Medicaid program that covers brand Crestor applies step therapy: the patient must have tried generic atorvastatin or generic rosuvastatin first [2].

Documenting Step Therapy Failures

Step therapy failures must be documented in the medical record, typically within 30 to 90 days of the trial. The prescriber documents the adverse event, the date of onset, the dose at which it occurred, and any labs (CK, ALT, AST) that support the claim. A creatine kinase (CK) level greater than 10 times the upper limit of normal constitutes clinical myopathy and is universally accepted as step therapy failure documentation [8].

The FDA label for rosuvastatin calcium notes that CK elevation and myopathy risk increase at higher doses and with concomitant use of cyclosporine, gemfibrozil, or certain antiretrovirals [1]. These drug-drug interactions constitute independent PA justification in many state PDL criteria documents, since generic and brand formulations contain identical active ingredients but patients may attribute symptom differences to excipients.

Can I Use HSA or FSA for Crestor?

Yes. Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) cover prescription drugs, including brand Crestor and generic rosuvastatin, as qualified medical expenses under IRS Publication 502 [13]. This applies whether you purchase the brand or generic, with or without insurance, at any licensed pharmacy. HSA/FSA funds can also pay for the prescriber visit required to obtain or renew the rosuvastatin prescription.

Medicaid enrollees generally do not have HSA accounts (Medicaid is not an HSA-compatible high-deductible health plan), but patients transitioning between Medicaid and commercial coverage may have HSA balances from prior employment. Those balances remain usable for Crestor purchases even after the HSA-eligible plan period ends.

Rosuvastatin Dosing Reference for Prescribers Filing PA

The FDA-approved dosing range for rosuvastatin calcium is 5 mg to 40 mg once daily [1]. The 2018 ACC/AHA guideline defines high-intensity therapy as rosuvastatin 20 mg or 40 mg daily [7]. Most Medicaid PA forms require the prescriber to state the dose, indication, and duration of intended therapy. Listing the ACC/AHA risk category (ASCVD risk 20%+ or established ASCVD) and the target LDL (less than 70 mg/dL for very high risk) alongside the dose strengthens the PA narrative and reduces the chance of denial.

A meta-analysis published in The Lancet (Cholesterol Treatment Trialists, 2010, N=170,000 patient-years) established that each 1 mmol/L reduction in LDL reduces major vascular events by approximately 22%, independent of baseline LDL [14]. Citing this data in a PA for a high-risk patient who requires the high-intensity rosuvastatin dose strengthens the clinical necessity argument significantly.

The FOURIER trial published in the NEJM (N=27,564) demonstrated that lower LDL is better in high-risk patients, supporting aggressive statin therapy as the first-line foundation before adding PCSK9 inhibitors [15]. Medicaid PA reviewers familiar with this literature are more likely to approve brand or high-dose rosuvastatin requests that cite guideline-concordant risk stratification.